Ahmedabad (Gujarat) [India], September 25: Intas Pharmaceuticals Limited ("Intas") has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of HETRONIFLY® (serplulimab, approve
Boston (Massachusetts) [US]/ Bangalore (Karnataka) [India], June 12: Zumutor Biologics Inc. "Zumutor", a Boston-based clinical stage Oncology Company developing first-in-class monoclonal antibody molecules targeting innate immunological pathways, today announced that the first patient was do
Researchers at The Florey have created a method using mRNA technology to specifically target the harmful protein tau, which accumulates in dementia patients suffering from Alzheimer's disease and other conditions.
Researchers at Osaka University have developed a new therapy technique for cytokine storm, a devastating inflammatory disease caused by an infection or severe burn.
Researchers discovered a previously unknown class of antibodies--immune system proteins that guard against disease--that appear to be capable of neutralising different strains of flu virus.
Researchers discovered that obinutuzumab, an antibody that targets a protein expressed on certain immune cells, was superior to placebo in preserving kidney function and preventing flares in patients with lupus nephritis - a kidney condition associated with the autoimmune disease lupus.
Professor Nicholas Tonks' laboratory identified an antibody that can suppress an enzyme that may aid in the spread of some breast tumours. With more research, the antibody may be able to give a feasible therapeutic treatment for the same breast cancers.
For far too long, cancer treatment has been a double-edged sword, with treatments designed to target cancer cells sometimes harming healthy cells as well.
An antibody developed in the lab of Cold Spring Harbour Laboratory Professor Nicholas Tonks can inhibit an enzyme that may aid in the spread of some breast tumours. With additional research, the antibody could provide a viable therapeutic treatment for the same breast tumours.
For far too long, cancer treatment has been a two-edged sword, with therapies designed to target cancer cells frequently wreaking damage on good cells as well.